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Is Rosuvastatin Really a More Efficient Therapeutic Option 
than Atorvastatin?
To the Editor–With regard to an article recently published
in this journal, we would like to state our disagreement
with the conclusion drawn. The conclusion stated that
rosuvastatin dominates atorvastatin because it is more
effective and less costly [1]. We disagree with this conclu-
sion because this cost-effective analysis was performed by
using just surrogate end points without clinically mean-
ingful outcomes and did not incorporate important safety
data about rosuvastatin.
It is very clear at present that when using statins the
most important outcome is neither the reduction of low-
density lipoprotein cholesterol (LDL-C) levels nor the
increase of high-density lipoprotein cholesterol levels
(both surrogate end points) but rather the decrease of
hard end points, such as myocardial infarction, hospital-
ization for unstable angina, stroke, death form cardiovas-
cular causes and sudden death. Therefore, it is essential to
realize the limitation of surrogate end points in assessing
both the efﬁcacy and also the potential harmful effects of
new medicines [2].
We do think that the efﬁcacy of new drugs should be
based on clear and reliable proof of clinically relevant
outcomes (cardiovascular events avoided, deaths averted,
lives saved, etc.) and the end result of performing a cost-
effectiveness analysis with surrogate end points is a par-
tial result that may confuse decision-makers and their
determinations. This is particularly important if we take
into account that every single statin has demonstrated
beneﬁt in terms of these clinically relevant outcomes in
large randomized clinical trials, with the exception of
rosuvastatin.
In addition, there is a large body of evidence suggest-
ing that LDL is not the only mechanism explaining the
beneﬁts of statins. The so-called pleiotropic effects should
also be taken into account. This is very well illustrated
with the results of two studies: the PROVE-IT and
REVERSAL [3,4], comparing atorvastatin 80 mg and
pravastatin 40 mg in patients with coronary heart disease.
In the PROVE-IT study, the beneﬁt of atorvastatin 80 mg
in terms of morbimortality was demonstrated in patients
with acute coronary syndromes. In the REVERSAL study,
the beneﬁt of atorvastatin 80 mg against pravastatin
40 mg couldn’t be solely explained by LDL. It was
hypothesized that a speciﬁc effect of atorvastatin 80 mg
on C-reactive protein (CRP) levels might be responsible
for the unexplained beneﬁt.
Based on this, in this cost-effectiveness analysis it had
been very useful the inclusion of other surrogate end
point, CRP levels, as it is an inﬂammatory marker that
has a strong predictive of future cardiovascular events [5].
In addition, the reduction of CRP levels is independent
of the decrease of LDL-C levels and it has been demon-
strated that there is a weak correlation between the per-
centage reductions in LDL-C and CRP levels [6], so the
only reduction of LDL-C does not predict very well the
decrease of cardiovascular events and death from cardio-
vascular causes. Although all statins diminish the levels of
both LDL-C and CRP, these are mostly independent of
each other and the fact of decreasing LDL-C levels does
not mean that the decline of CRP levels will be also
signiﬁcantly.
Atorvastatin has demonstrated that it signiﬁcantly
reduces CRP levels and in a higher quantity than other
statins do [4,7] while the degree of CRP levels reduction
is unclear in rosuvastatin [8]. Therefore, a plausible con-
clusion is that atorvastatin produces a higher reduction in
hard efﬁcacy end points than rosuvastatin. This debate
will be resolved when the JUPITER trial is completed. At
the moment this trial is ongoing and will determine
whether long-term use of rosuvastatin can reduce CRP
levels and the rate of coronary events [9].
This conﬁrms our thoughts that the results of this cost-
effectiveness analysis should be considered with a lot of
precaution and it would be very dangerous to make deci-
sions with them.
On the other hand, in a recent published article it has
been described that rosuvastatin may produce higher
rates of adverse events report (AER) (rhabdomyolysis,
proteinuria, nephropathy, and renal failure) than atorvas-
tatin, simvastatin, and pravastatin in common clinical
practice in the United States [10]. This analysis captures
the real-life population exposure collected in the Food
and Drug Administration AERs system and offers advan-
tages over safety data coming from controlled premarket-
ing clinical trials.
We believe that it is necessary to incorporate these data
into the decision analytic model, to complete safety data
from clinical trials. Patients treated with rosuvastatin in
who appear an AER probably need either a dose reduc-
tion or even a withdrawal of this statin, so the ﬁnal efﬁ-
cacy in reducing LDL-C levels would be lower. In this
case, atorvastatin could be a more efﬁcient option than
rosuvastatin.
Although leading to mayor methodological caveats the
CRP and AER issues are not the most important problems
of this economic evaluation. The fundamental limitation
is based in a much more obvious rationale: when morbi-
mortality beneﬁts have been demonstrated for a number
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of drugs within a particular group, such as statins, as per
large randomized clinical trials, a surrogate end point
simply cannot be used to claim a superior efﬁcacy for the
only drug (rosuvastatin) without any evidence of efﬁcacy
in terms of morbimortality.
Cost-effectiveness analysis is a very useful tool for
decision-makers to allocate properly available resources.
However, if it is not correctly conducted or it is performed
with inappropriate data, it is possible that at the end
decision-makers may make incorrect decisions with the
consequent being ineffective allocation of resources.
Therefore, we believe that rosuvastatin should demon-
strate efﬁcacy in terms of morbimortality before trying to
demonstrate cost-effectiveness.
For these reasons, we do think that this cost-
effectiveness analysis should be considered a preliminary
exploratory exercise, pending on the results of morbimor-
tality and safety of rosuvastatin from large randomized
clinical trials. Otherwise, conclusions are potentially mis-
leading for decision-makers.—Javier Soto, MD, PhD, and
Jaime Fernandez de Bobadilla, MD, Health Outcomes
Research, Medical Unit, Pﬁzer, Madrid, Spain.
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The authors reply . . .
Formulary Decision-Making Should Rely on 
the Best Available Evidence
To the Editor—Evidence of effectiveness and cost-
effectiveness is inherently dynamic in nature. Cost-
effectiveness models based on the best data available at
the time are an important contribution to evidence-based
decision-making if they reveal the likely outcomes of var-
ious scenarios and quantify the degree of uncertainty
around the apparently optimal approach. Cost-effective-
ness models also illustrate the trade-offs inherent in each
potential alternative available to the decision-maker and
should be updated as new evidence becomes available.
In 2000, The Academy of Managed Care Pharmacy
issued its ﬁrst Format for Formulary Submissions, which
provided US payers with a new tool to proactively request
clinical and economic data from health technology man-
ufacturers. The Format, which has been revised substan-
tially in recent years, is now used by health-care
organizations covering some 150 million lives in the
United States [1]. This guidance recommends that dossi-
ers for new drug products be requested by health plans
approximately 6 months before launch, and explicitly
calls for the use of economic models “to inform decisions
about the value or cost-effectiveness of pharmaceuticals,
biologics, and vaccines.” Such models are to be based on10.1111/j.1524-4733.2006.00112.x
